Oxidative stress in Alzheimer's disease: In vitro therapeutic effect of amniotic fluid stem cells extracellular vesicles by Gatti, M. et al.
Research Article
Oxidative Stress in Alzheimer’s Disease: In Vitro Therapeutic
Effect of Amniotic Fluid Stem Cells Extracellular Vesicles
Martina Gatti ,1 Manuela Zavatti ,1 Francesca Beretti ,1 Daniela Giuliani ,1
Eleonora Vandini ,1 Alessandra Ottani ,1 Emma Bertucci ,2 and Tullia Maraldi 1
1Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy
2Department of Medical and Surgical Sciences for Mothers, Children and Adults, University of Modena and Reggio Emilia,
Azienda Ospedaliero Universitaria Policlinico, Via Del Pozzo 71, 41124 Modena, Italy
Correspondence should be addressed to Tullia Maraldi; tullia.maraldi@unimore.it
Received 27 May 2020; Revised 20 July 2020; Accepted 31 July 2020; Published 24 October 2020
Guest Editor: Raquel Rodriguez-Diez
Copyright © 2020 Martina Gatti et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Alzheimer’s disease (AD) is characterized by abnormal protein aggregation, deposition of extracellular β-amyloid proteins (Aβ),
besides an increase of oxidative stress. Amniotic fluid stem cells (AFSCs) should have a therapeutic potential for
neurodegenerative disorders, mainly through a paracrine effect mediated by extracellular vesicles (EV). Here, we examined the
effect of EV derived from human AFSCs (AFSC-EV) on the disease phenotypes in an AD neuron primary culture. We observed
a positive effect of AFSC-EV on neuron morphology, viability, and Aβ and phospho-Tau levels. This could be due to the
apoptotic and autophagic pathway modulation derived from the decrease in oxidative stress. Indeed, reactive oxygen species
(ROS) were reduced, while GSH levels were enhanced. This modulation could be ascribed to the presence of ROS regulating
enzymes, such as SOD1 present into the AFSC-EV themselves. This study describes the ROS-modulating effects of extracellular
vesicles alone, apart from their deriving stem cell, in an AD in vitro model, proposing AFSC-EV as a therapeutic tool to stop the
progression of AD.
1. Introduction
Neurodegenerative diseases are characterized by progressive
damage in neural cells which leads to compromised motor
or cognitive functions. Alzheimer’s disease (AD) is the sixth
leading cause of death in the United States, and it is the most
widespread neurodegenerative disorder, which significantly
affects people’s daily lives [1]. The pathophysiology of AD
is mainly associated with the extracellular deposition of amy-
loid beta (Aβ) plaques and the accumulation of intracellular
tau neurofibrillary tangles (NFT) [2]. The mechanisms
behind Aβ neurotoxic action could be several; many of which
flow into the reactive oxygen species (ROS) generation. For
example, Aβ plaques can reduce calcium ion storage in endo-
plasmic reticulum, then resulting in cytosolic Ca2+ overload.
As a consequence of cytosolic Ca2+ increase, endogenous glu-
tathione (GSH) levels are reduced and ROS are overaccumu-
lated inside the cells [3]. In addition, Aβ proteins can directly
cause free radical formation via the activation of NADPH
oxidase [4]. Indeed, ROS are chemically reactive molecules
that are involved in the pathogenesis of neurodegenerative
diseases. Although it is not yet understood whether ROS
could be the triggering factor in neurodegenerative diseases,
they probably are to be considered exacerbating players in
the disease progression through oxidative damage [5, 6]. Of
note is that neuronal cells are particularly vulnerable to oxi-
dative damage because of their high polyunsaturated fatty
acid content in membranes, high oxygen consumption, and
weak antioxidant defense [7].
Moreover, ROS can regulate JNK/stress-activated protein
kinase pathways. The activation of these cascades is linked to
the hyperphosphorylation of tau proteins and Aβ-induced
cell death [8]. The pathogenesis of several neurodegenerative
disorders, such as AD and Parkinson’s disease, is associated
with the accumulation of misfolded proteins. Inflammatory
response in the brain can be activated to counteract the
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aggregation of these modified proteins, while inducing a
marked ROS release and subsequent oxidative stress (OS)
[9, 10]. Therefore, a vicious circle, in which the ROS level
increases, seems to be triggered. Considering the pivotal roles
of OS in neurodegenerative diseases, the regulation of ROS
levels could be a promising target to slow down neurodegener-
ation and alleviate associated symptoms. However, most of the
antioxidants which have been studied, proved scarcely suc-
cessful in clinical trials, which may be due to their scarce dis-
tribution and inherent difficulties to cross the blood brain
barrier and reach the target sites. Despite the evidence that dif-
ferent classes of antioxidants are neuroprotectants in vitro, the
clinical data is not consistent [11]. Based on these consider-
ations, finding a way to combine neuroprotective, anti-inflam-
matory, and endogenous antioxidant manipulation properties
may hold great promise to counteract AD symptoms.
Mesenchymal stem cells (MSCs) and, in particular, MSC-
derived extracellular vesicles (EV), could be proposed as a
strategic approach to contrast this pathology. Indeed, MSC-
EV—carrying lipids/proteins/enzymes/microRNAs endowed
with anti-inflammatory, Aβ degrading systems, and neuro-
trophic activities [12]—could be the therapeutic tool combining
different properties able to restore the synaptic function, prevent
neuronal death, and slow down memory impairment in AD.
Several demonstrations of the effect of MSC-EV on low-
ering AD markers are present in the literature on the in vitro
AD cell models. The exposure to MSC-EV was first investi-
gated in a cellular model of AD by using EVs isolated from
adipose tissue MSCs. The incubation of MSC-EVs to N2A
neuroblastoma cells reduced both secreted and intracellular
Aβ peptide levels [13]. Similarly, more recently MSC trans-
well coculture with rat neurons exposed to soluble oligomers
of the Aβ peptide (AβOs) induced internalization and degra-
dation of AβOs, release of extracellular vesicles containing
active catalase, and selective secretion of interleukin-6, inter-
leukin-10, and vascular endothelial growth factor to the
medium [14].
Amniotic fluid stem cells (AFSCs) are a feasible variety of
MSC for experimentation purposes, owing to their pluri/mul-
tipotency, abundance, andminimal ethical considerations.We
recently reported that AFSC secretory factors have antiapop-
totic and anti-inflammatory effects [15, 16]. Although the
paracrine function of stem cells is reported to have a therapeu-
tic potential in many neurological disorders, the effects of
AFSC-derived extracellular vesicles (AFSC-EV) on the cellular
phenotypes of AD have not yet been investigated. A primary
culture of neurons, derived from 5xFADmice [17, 18], an ani-
mal model of AD, was here employed to investigate the effect
of an enrichment in extracellular vesicles obtained from
human AFSCs on morphological features, apoptosis/viability
parameters, and AD markers. We focused our attention on
the EV-modulation of ROS levels as pivotal key to counteract
neurodegenerative diseases.
2. Materials and Methods
2.1. Amniotic Fluid Collection. The AFSCs were obtained
from amniotic fluids collected from 4 healthy pregnant
women at the 16th week of gestation who underwent amnio-
centesis for maternal request (not for foetal anomalies) at the
Unit of Obstetrics & Gynecology, IRCCS-ASMN of Reggio
Emilia and at the Policlinico Hospital of Modena (Italy).
The amniocentesis was performed under continuous ultra-
sound guidance, in a sterile field, with 23-Gauge needles.
The risks related to the procedure and the purpose of the
study were explained to all patients before the invasive proce-
dure and the ob-gyn specialist collected a signed consent
before starting the exam (protocol 2015/0004362 of
02.24.2015 and protocol 360/2017 dated 12.15.2017
approved by Area Vasta Emilia Nord). For this study, super-
numerary (unused) flask of AF cells, cultured in the Labora-
tory of Genetics of TEST Lab (Modena, Italy) for 2 weeks,
was used.
2.2. Adult Human Tissue Isolation and Cell Culture. AFSCs
were isolated as previously described [19]. Human amnio-
centesis cultures were harvested by trypsinization and sub-
jected to c-kit immunoselection by MACS technology
(Miltenyi Biotec, Germany). AFSCs were subcultured rou-
tinely at 1 : 3 dilution and not allowed to grow beyond the
70% of confluence. AFSCs were grown in culture medium
(αMEM) supplemented with 20% fetal bovine serum (FBS),
2mML-glutamine, 100U/ml penicillin, and 100μg/ml strep-
tomycin (all from EuroClone Spa, Milano, Italy).
2.3. Extracellular Vesicle Isolation from ConditionedMedium.
AFSCs were grown in 75 cm2 flask until subconfluence
(around 1 × 106 cells). Before extracellular vesicle extraction,
the cells were maintained for 4 days in 10mL culture medium
deprived of FBS in order to exclude the contamination by
extracellular vesicles comprised into FBS solution. The
secreted part of conditioned medium (CM) was then concen-
trated up to 2mL by using centrifugal filter units with 3K
cutoff [15]. Then, the concentrated CMwas treated with total
exosome isolation solution from cell culture media (Invitro-
gen, Life Technologies, CA. USA), according to the manufac-
turer’s instructions. The pellet, enriched in exosomes
although it can be not a pure extraction, was collected and
quantified by the Bradford method. To obtain a sample for
Western blot analysis, the pellet was resuspended in lysis
buffer. We previously showed morphological characteriza-
tion of extracellular vesicles by electron microscopy [15].
The surnatants deriving from the isolation protocol
(-EV) were collected as well. The neuroblastoma cell line
SH-SY 5Y, cultured in 1 : 1 DMEM (EuroClone Spa, Milano,
Italy)/F12 (EuroClone Spa, Milano, Italy), 1% fetal bovine
serum (FBS) (Microgem, Naples, Italy), 2mM glutamine,
100U/ml penicillin and 100μg/ml streptomycin, 1mM
Not-Essential Amino Acids (all from EuroClone Spa,
Milano, Italy), was exposed to 10μM Aβ 1-42 (Anaspec
Inc., California, USA) for 24h in order to test EV and -EV
in a simple AD in vitro model. The same protein concentra-
tion of +EV and –EV was added to neuronal cells 3 days
before Aβ treatment.
2.4. Animals. 5xFAD mice cooverexpress a triple-mutant
human amyloid precursor protein (APP) (Swedish mutation:
K670N, M671L; Florida mutation: I716V; London mutation:
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V717I) and a double-mutant human presenilin 1 (PS1)
(M146L and L286V mutations) transgenes under the tran-
scriptional control of the neuron specific Thy-1 promotor.
Progenitors were purchased from Jackson Laboratories, Bar
Harbor, and 5xFAD line was maintained by crossing hemizy-
gous 5xFAD mice with B6SJL/J breeder. Mice were kept in
conditioned rooms with stable temperature (22 ± 1°C) and
humidity (60%), on a light/dark cycle of 12 hours, with food
and water ad libitum. All animal procedures were approved
by the Committee on Animal Health and Care of the Univer-
sity of Modena and Reggio Emilia (protocol number:
974/2016-PR del 13-10-2016) and conducted in accordance
with National Institutes of Health guidelines.
For genotyping procedure, APP and PS1 lines were ana-
lyzed as previously reported (Gordon et al. 2001). Tail samples
from WT and 5xFAD mice were examined by using primers
supplied by Jackson Laboratories to identify either the muta-
tion or the wild-type allele with the polymerase chain reaction
(PCR): forward, 5′-AGGACTGACCACTCGACCAG-3′ and
reverse, 5′-CGGGGGTCT AGTTCTGCAT-3′ for APP trans-
genes; forward, 5′-CTAGGCCACAGAATTGAAAGATCT-3′
and reverse 5′-GTAGGTGGAAATTCTAGCATCA-TCC-3′
for positive control; forward, 5′-AAT AGA GAA CGG CAG
GAG CA-3′ and reverse 5′-GCC ATG AGG GCA CTA
ATC AT-3′ for hPRES transgene. DNA was polymerized at
94°C for 3min; 35 cycles of 94°C for 15 s; 54°C for 1min;
72°C for 1min; and 72°C for 2min; stored at 4°C. The PCR
products were run on a 1% agarose gel, using ethidium bro-
mide ultraviolet (UV) detection for the bands at 377bp (APP
transgene) or 324bp (positive control) and 608bp (hPRES).
2.5. Preparation of Primary Cultured Cortical Neurons. Cor-
tical and hippocampal neurons from wild type (WT)
(N = 18) and 5xFAD (FAD) (N = 25) mice were collected
within 24 h from birth [20]. Brains were removed, meninges
were gently peel off, and cortical and hippocampal tissue dis-
sected. Tissues were incubated in a buffer solution containing
HBSS (Hanks’ Balanced Salt Solution, GIBCO, Milan, Italy)
with BSA 0.3% (Microgem Srl, Naples, Italy) and trypsin
0.025% (EuroClone, Milan, Italy) at 37°C for 15min. Then,
tissues were triturated with a plastic 1000μl pipette tip in a
HBSS buffer containing 0.004% deoxyribonuclease I (DNA-
seI, Sigma Aldrich) and 10% fetal bovine serum (FBS, Micro-
gem Srl). After centrifugation at 500 g for 5min, cells were
suspended in Neurobasal medium supplemented with 2%
B27 (GIBCO, Thermo Fisher Scientific, Monza, Italy),
2mM glutamine, 100U/ml penicillin and, 100μg/ml strepto-
mycin (EuroClone) and plated on poly-L-lysine (Merck
Millipore, Milan, Italy) coated plastic or coverslips at 0.5
x106 cells/cm2. Cells were maintained at 37°C and 5% CO2.
After 48 h, cells were treated with 5μM cytosine β-D-arabi-
nofuranoside (Sigma Aldrich) for 24 h.
For in vitro experiments, 10μg of extracellular vesicles,
obtained from the two human samples of AFSCs, resus-
pended in PBS, were added to 1 × 106 cells at DIV (days
in vitro) 3 for 7 up to 14 days.
Wortmannin (Sigma Aldrich) treatment was performed
for 2 h prior the EV exposure.
2.6. Cellular Morphology. Cellular images were acquired
using EVOS XL Core Cell Imaging System (Thermo Fisher
Scientific, Vantaa, Finland). Parameter and area were mea-
sured with ImageJ using image pixels as scale. Cellular elon-
gation was calculated using the following formula:
Cellular elongation = p2/4π ∗A ð1Þ
where p is the cellular perimeter, π is equivalent to 3.14, and
A represents the cellular area.
2.7. MTT Assay. Primary neurons were seeded in 96-well
plates in 200μl of a culture medium, 4 replicates for each
condition. At the end of each experiment, 0.5mg/ml MTT
was added and incubated for 3 h at 37°C. After incubation,
the medium was removed and acidified isopropanol was
added to solubilize the formazan salts [21]. The absorbance
was measured at 570nm using a microplate spectrophotom-
eter (Appliskan, Thermo-Fisher Scientific, Vantaa, Finland).
2.8. ROS and Glutathione Detection. To evaluate intracellular
ROS levels, dichlorodihydrofluorescein diacetate (DCFH-
DA) assay was performed similarly to as previously described
[22]. Cells were seeded in a black 96-well plate, 4 replicates
for each condition. Cell culture medium was removed, and
the 5μM DCFH-DA was incubated in PBS for 30min, at
37°C and 5% CO2. The cell culture plate was washed with
PBS, and fluorescence of the cells was read at 485nm (excita-
tion) and 535nm (emission) using the multiwall reader
Appliskan (Thermo-Fisher Scientific, Vantaa, Finland). Cel-
lular autofluorescence was subtracted as a background using
the values of the wells not incubated with the probe.
Similarly, to evaluate reduced GSH levels, monochlorobi-
mane (MCB) assay was performed as previously reported
[23]. Cell culture medium was removed, and 50μM MCB
was incubated in PBS for 30min, at 37°C and 5% CO2. The
cells were washed in PBS, and fluorescence of the cells was
measured at 355nm (excitation) and 460nm (emission).
2.9. Quantification of Aβ by ELISA. Secreted amyloid beta
peptide1-42 (Aβ42) from primary cultured neurons was ana-
lyzed in medium exposed to neurons by BETA-APP42
ELISA Kit (Human) (Aviva Systems Biology, San Diego,
CA, USA).
Medium from 5xFAD cells treated with AFSC-EV for 7
days and control were collected and then centrifuged at
20°C 1200 rpm for 10 minutes in order to remove cellular
debris.
Supernatants were concentrated about 10 times by lyoph-
ilization with LIO5P (5Pascal, MI, Italy) (Sun et al. 2014).
Freeze-dried powder obtained from 6ml of medium exposed
to neurons was rehydrated with 600μl of purified water and
stored at +4°C until test. Concentrated media were used for
the ELISA assay.
Aβ ELISA was performed according to the manufac-
turer’s protocol of ELISA kit (Aviva Systems Biology, San
Diego, CA, USA).
2.10. Cellular Extracts Preparation. Cell extracts were
obtained as previously described [24]. Briefly, subconfluent
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cells were extracted by addition of lysis buffer (20mM Tris-
Cl, pH7.0; 1% Nonidet P-40; 150mM NaCl; 10% glycerol;
10mM EDTA; 20mM NaF; 5mM sodium pyrophosphate;
and 1mM Na3VO4) and freshly added Sigma Aldrich Prote-
ase Inhibitor Cocktail and para-Nitrophenylphosphate
(pNPP) at 4°C for 20min. Lysates were sonicated, cleared
by centrifugation, and immediately boiled in SDS reducing
sample buffer.
2.11. SDS PAGE and Western Blot. Whole cell lysates from
primary neurons and AFSC-EV were processed as previously
described [25]. Primary antibodies were raised against the
following molecules: Actin, Nox4 (Sigma-Aldrich, St Louis,
MO, USA), Akt, SOD1, SIRT1, gp91phox, TrxR1, TrxR2,
Gpx1, LC3β, PARP, TIA-1 (Santa Cruz Biotechnology, CA,
USA), pAktser473 (Cell Signaling Technology, MA, USA), β-
Amyloid clone 6E10 (Bio Legend, CA, USA), pTauser422 (Ori-
Gene Technologies, MD, USA), Rab5 (Lonza, SC, USA), CD9
(Life Technologies, CA, USA), CD81 (Thermo Fisher Scien-
tific, MA, USA), Bcl-2 (Bio Source, CA, USA).
Secondary antibodies, used at 1 : 3000 dilution, were all
from Thermo Fisher Scientific (Waltham, MA, USA).
2.12. Immunofluorescence and Confocal Microscopy. For
immunofluorescence analysis, primary neurons seeded on
coated coverslips were processed and confocal imaging was
performed using a Nikon A1 confocal laser scanning micro-
scope, as previously described [26].
Primary antibodies to detect βTubulin III (Millipore, CA,
USA), pTauser422 (OriGene Technologies, MD, USA), and
6E10 (Bio Legend, CA, USA) were used following datasheet
recommended dilutions. Alexa secondary antibodies
(Thermo Fisher Scientific, Waltham, MA, USA) were used
at 1 : 200 dilution.
The confocal serial sections were processed with ImageJ
software to obtain three-dimensional projections. The image
rendering was performed by Adobe Photoshop software.
For apoptosis detection, after 3 washes with 50μl of bind-
ing buffer (10mMHEPES, pH7.5, containing 140mMNaCl,
and 2.5mM CaCl2), the specimen was incubated for 15
minutes with 50μl of double staining solution (binding
buffer containing 0.25μl of annexin V-FITC and 0.25μl of
propidium iodide (PI); BD Pharmingen™, Erembodegem,
Belgium). Finally, the specimen was washed 5 times with
50μl of binding buffer, mounted with 15μl of binding buffer,
and visualized under fluorescence microscopy [24].
2.13. Statistical Analysis. In vitro experiments were per-
formed in triplicate. For quantitative comparisons, values
were reported as mean ± SEM based on triplicate analysis
for each sample. To test the significance of observed differ-
ences among the study groups, one-way ANOVA with Bon-
ferroni post hoc test or Student t test (where only two
samples were compared) were applied. A p value < 0.05 was
considered to be statistically significant. FAD and FAD +
EV samples were compared to WT sample and the ANOVA
analysis was shown with asterisk over the column; the same
analysis revealed that the comparison between FAD and
FAD + EV and the significativity was shown with additional
asterisks over lines. Statistical analysis and plot layout were
obtained by using GraphPad Prism® release 6.0 software.
3. Results
3.1. Morphological Characterization of Cultured Neurons
Exposed to AFSC-EV. FAD neurons appeared unhealthy, if
compared to WT neurons, since neurodegeneration in FAD
neurons was prominent, as indicated by shrunken nuclear
envelope (Figure 1(a) lower images) and neurite deteriora-
tion (Figure 1(a) upper images), as shown in graphs display-
ing number, length, and thickness (Figure 1(b)). The effect of
14 days EV treatment was to counteract the nuclear envelope
modification and to avoid neurite loss, since the measures of
neurite parameters were brought back similar to the WT
ones. Similar results were obtained in all the experiments
shown here below, despite individual variability due to AFSC
samples obtained from different women.
3.2. ROSModulation by AFSC-EV in FADNeurons. The anal-
ysis of ROS content shown in Figure 2(a) revealed that FAD
neurons displayed a higher ROS level compared to WT cells,
as expected. Conversely, GSH is lower in FAD neurons, even
though not significantly. However, the exposure to AFSC-EV
reduced the ROS content, while allowed the increase in GSH
level.
Then, we investigated the expression of proteins related
to ROS modulation, and WB analysis (Figure 2(b)) demon-
strated that antioxidant enzymes, such as SOD1, thioredoxin
reductases TrxR1 and TrxR2, and glutathione peroxidase 1
(Gpx1), were all more present in FAD+EV neurons than in
FAD cells. The comparison between FAD and WT did not
show differences, excepted for TrxR1. The increase in TrxR1
expression in FAD neurons could be related to an intracellu-
lar defense against the ROS rise that we previously observed.
In parallel, the FAD neurons displayed a higher level of
Nox4, a ROS producing enzyme constitutively active. Indeed,
it does not need cytosolic subunits for activation, though they
are able to modulate Nox4 activity. This effect was reduced, at
least in part, by the presence of EV. Meanwhile, no differ-
ences were observed for the expression of gp91phox, the typ-
ical subunit of Nox2, another NADPH oxidase expressed
into the brain. Aside from phagocytic cells, including microg-
lia, Nox2 is also found in endothelial cells and neurons [27].
Interestingly, the characterization of AFSC-EV revealed
that all the samples, even though with different level of exo-
some markers (CD9, CD81 and Rab5), carried similar levels
of SOD1 protein.
3.3. Effect of AFSC-EV on Apoptotic and Autophagic
Pathways. Neuronal viability in FAD neurons was signifi-
cantly decreased by 25% in DIV (days in vitro) 14 cultures,
compared to WT neurons (Figure 3(a)). In parallel, the anal-
ysis of apoptosis by annexin V and propidium iodide (PI)
demonstrated that the apoptotic pathway is involved, as
expected (Figure 3(b)). However, the presence of EV signifi-
cantly restored cell viability and reduced annexin V and PI
staining (Figures 3(a) and 3(b)). In accordance with this
result, our immunoblotting data further demonstrated an
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increased activation of Akt, a key signaling molecule for neu-
ronal survival, indicated by the higher phosphorylation, with
a concomitant activation of Bcl-2, an anti-apoptotic marker,
in FAD+EV neurons (Figure 3(c)). Moreover, the cleavage of
PARP, significantly higher in FAD neurons, compared to
WT, was reduced by the EV-treatment. These results suggest
that the decreased cell viability associated with the activation
of apoptotic pathway in FAD neurons could be contained by
AFSC-EV.
In order to test the role of the PI3K/Akt pathway, we used
wortmannin, selective and irreversible inhibitor of phos-
phatidylinositol 3-kinase (PI3K). The results on ROS and
apoptosis (Supplementary Figure I) show that the
inhibition of the PI3K/Akt pathway partially affects the
extracellular vesicle modulation, suggesting its involvement
in the EV efficacy.
Autophagic pathways were also modulated through AFSC-
EV content, as demonstrated by the increased levels of SIRT1, a
NAD-dependent class III histone and nonhistone protein dea-
cetylase, and LC3β protein. Both proteins are markers of
autophagy, and their expression is altered during AD [28].
3.4. Reduction of AD Markers in the Presence of AFSC-EV.
Finally we investigated the modulation of intracellular AD
markers, by using the antibody 6E10, specific for human
Amyloid precursor protein (APP), Aβ oligomers [29], and
molecules generated from cleavage of APP by secretases
[30], and anti-Tau phosphorylated in Serine 422 [31], a path-
ological epitope and one of the markers of neurofibrillary
degeneration: both are neuropathological hallmarks of Alz-
heimer’s disease.
Our immunoblotting results demonstrated that levels of
APP, Aβ oligo, and p-Tauser422 were reduced in EV-treated
AD neurons (Figures 4(a) and 4(c)). These results were con-
firmed by immunofluorescence images shown in Figures 4(b)
and 4(d), where the signals of 6E10 and p-Tauser422 dropped
down in EV-samples.
Furthermore, the quantitative detection of secreted Aβ42
demonstrated the positive effect of AFSC-extracellular vesicle
on FAD neurons, since the production of Aβ in AD neurons
was decreased after treatment.
4. Discussion
In the last decades, stem cells have been in the spotlight as a
promising candidate for regenerative medicine. Amongst
these, mesenchymal stromal cells from the amniotic fluid
(AFSCs) have been shown to favor tissue repair and





































































Figure 1: Effect of AFSC-EV supplementation on cell morphology of AD primary neurons in vitro. (a) Cells were incubated for 14 days with
neurobasal medium 2% B27 containing AFSC-EV replaced once a week. Representative images with DAPI (blue) and βTubulinIII (red) or
lamin A (red) signals of WT and FAD cells incubated or not with EV are shown. Scale bar = 10μm. In white squares are shown
representative doubled magnification images. (b) Mean measures in percentage ± SEM of number, length, and diameter of neurites
visualized in 10 fields for each condition are shown in graphs. ∗p value < 0.05; ∗∗p value < 0.01; ∗∗∗p value < 0.001.
































































































































































































































































































































































Figure 2: Effect of AFCS-EV supplementation on ROS modulation in AD primary neurons. (a) ROS and GSH content was measured with
fluorescent probes, as described in Section 2.8, after 7 days of AFSC-EV exposure. ∗p value < 0.05; ∗∗p value < 0.01; ∗∗∗∗ p value < 0.0001. (b)
Western blot analysis of total lysate of WT, FAD cells treated or not with AFSC-EV, then revealed with the indicated primary antibodies. The
graphs represent the mean ± SEM of densitometric analysis of 3 experiments, normalized to actin values. ∗p value < 0.05; ∗∗p value < 0.01;
∗∗∗p value < 0.001. (c) Western blot analysis of AFSC-extracellular vesicles derived from 4 donors, then revealed for CD9, CD81, and
Rab5, as exosome markers, SOD1, and actin. The graph represents the mean ± SEM of densitometric analysis of 3 experiments,
normalized to actin values. ∗p value < 0.05.
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regeneration after transplantation in animal models of
inflammatory-based diseases. The benefits of transplanted
amniotic cells were observed despite cell engraftment in
injured tissue, thus suggesting that these cells produce bioac-
tive factors able to mediate the above-mentioned effects
through paracrine signaling [32]. Stem cells secrete various
molecules such as growth factors and extracellular vesicles
[33], able to modulate oxidative stress. Since endogenous
and microenvironmental oxidative stress may be a pivotal
factor exacerbating pathways driving to neuronal loss in
AD [34], here, we explored the effects of a suspension
enriched in exosomes, derived from AFSCs in culture, on
the viability of neurons obtained from ADmice, and demon-
strated that the redox state is deeply modified by such
exposure.
We are aware that the used isolation technique could give
possible differences compared to ultracentrifugation and SEC
protocols: indeed, it has been demonstrated that this kit gave
the highest yield but the preparation showed broader size-
distribution likely due to microvesicle co-precipitation and
had the least dispersion stability [35]. Therefore, in order
to compare the efficacy of these extracellular vesicles,
obtained with this commercial kit, and the other part of
secretome, namely, the supernatant derived from such iso-
lation process (-EV), we performed viability and ROS
analyses on the recognized in vitro AD model, SH-SY 5Y
exposed to Aβ, treated with +EV or -EV. The results,
shown in supplementary Figure II, confirmed our
previous observations on other cell types (human
lymphocytes) [15]: actually, the presence of EV showed
an increase in the viability of Aβ-treated cells and a
decrease in ROS content, but - EV did not exert any
modulation, supporting the validity of the extracellular







































































































































































































































































































Figure 3: Effect of AFSC-EV supplementation on apoptotic and autophagic pathways of AD primary neurons in vitro. (a) Representative
graph showing MTT viability of WT and FAD cells treated or not with AFSC-EV. ∗∗∗∗p value < 0.0001. (b) Representative graph showing
the percentage of positive cells to Annexin V/Propidium Iodide assay, as described in the 2.12 section. ∗p value < 0.05; ∗∗p value < 0.01.
(c) Western blot analysis of total lysate of WT, FAD cells treated or not with AFSC-EV, then revealed with anti-Bcl-2, anti-PARP, anti-
pAkt, anti-LC3β, and anti-SIRT1 antibodies. The graphs represent the mean ± SEM of densitometric analysis of 3 experiments,
normalized to actin values. ∗p value < 0.05; ∗∗p value < 0.01; ∗∗∗p value < 0.001.
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Figure 4: Continued.
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Such modulation, described above, occurred in parallel
with a decrease in the accumulation of extracellular amy-
loid-β. Accordingly, the key biochemical change in AD is
the modification by the ROS of Aβ into toxic products, which
progressively aggregate into senile plaques promoting apo-
ptosis [36]. Indeed, considerable evidence now indicates that
soluble Aβ oligomers, monomers, and protofibrils, rather
than amyloid deposits, are the main toxic agents in AD
[37]. Consistently, we observed a decrease in the APP and
Aβ oligomers intracellular content as well.
In line with this consideration, we noticed that the rescue
of neurons viability exposed to AFSC-EV is accompanied by
a decline in apoptotic markers. Moreover, morphological
aspects, deriving from neurotoxicity, such as neurite and
nuclear envelope modifications, were prevented. Typical
nuclear abnormalities consisting of altered nuclear envelo-
pe/lamina structure were observed in several age-related dis-
eases [38] and in AD as well [39].
Other AD features were also taken into consideration,
such as impairment of autophagy and Tau phosphorylation,
since both of them are, to a certain extent, linked to redox
unbalance. Indeed, oxidative stress also supports a process
of progressive failure of autophagy in neurons and promotes
Tau phosphorylation, then causing impaired memory deficit
[1]. Moreover, growing evidence suggests that APP process-
ing and Aβ release are upstream of Tau pathology. Tau
hyperphosphorylation is implicated in autophagy dysfunc-
tion, and increased levels of lysosomal protease occur in
AD patients [40]. Indeed, we noticed that FAD samples
showed a higher level of LC3B, the protein involved in the
formation of autophagosomal vacuoles, an event probably
due to an early cellular response to the need to eliminate pro-
tein aggregates, which remains insufficient to counteract the
progress of the pathology. More interestingly, we observed
that the presence of extracellular vesicle treatment induced
a further increase in the autophagic marker LC3B. EV
administration positively regulated SIRT1 expression as well.
This effect supports the proposed role of extracellular vesicles
in regulating ROS levels and autophagy, since sirtuins are
antioxidant and antiapoptotic and crucial mediators for lyso-
somal autophagy regulation, which plays a pivotal role in the
AD [41].
Moreover, ROS has been shown to regulate autophagy
through several signaling pathways such as PI3K/Akt,
AMPK. These pathways appear to be crucial in AD since
related to the Tau protein hyperphosphorylation. In addi-
tion, the PI3K/Akt pathway has been shown to play a critical
role in the neuroprotection and inhibiting apoptosis via the
enhancing expression of the SODs [42]. Similarly, here, we
demonstrated that the presence of extracellular vesicles
favored the activation of Akt, being this protein more phos-
phorylated after EV-exposure. Moreover, in case of inhibi-
tion of the PI3K/Akt pathway, the extracellular vesicle
modulation ROS and apoptosis was affected, suggesting its
partial involvement in the EV efficacy. All these data are in
line with the observations carried out on a model of AD, gen-
erated by treating in vitro SH-SY 5Y cells (a human neuro-
blastoma cell line) with Aβ, where the authors showed that
BM-MSCs stimulated autophagy in diseased neurons
exposed to toxic protein aggregates and the enhancement of
aggregate degradation, thus increasing neuronal survival
[43].
Interestingly, we then confirmed that the treatment with
AFSC-extracellular vesicles prevented the phosphorylation of
Tau protein at serine 422, the typical site of phosphorylation
occurring in AD [31], suggesting that the redox regulation by
extracellular vesicles may affect the whole AD pathogenesis.




















Figure 4: Effect of AFSC-EV supplementation on ADmarkers of AD primary neurons in vitro. (a) Western blot analysis of total lysate ofWT
and FAD cells treated or not with AFSC-EV, then revealed with anti-p-Tauser422 antibody. The graph represents the mean ± SEM of
densitometric analysis of 3 experiments, normalized to actin values. ∗∗∗p value < 0.001. (b) Representative images showing DAPI (blue)
and p-Tauser422 (red) signals of FAD cells incubated or not with EV. Scale bar = 10μm. (c) Western blot analysis of total lysate of WT,
FAD cells treated or not with AFSC-EV, then revealed with 6E10 antibody. APP (100 kDa) and Aβ oligo (16 kDa) bands, with 6E10, are
shown. The graphs represent the mean± SEM of densitometric analysis of 3 experiments, normalized to actin values. ∗p value < 0.05; ∗∗p
value<0.01; ∗∗∗ p value<0.001. (d) Representative images with DAPI (blue) and APP (green) signals of FAD cells incubated or not with
AFSC-EV are shown. Scale bar = 10 μm. (e) Percentage of secreted β-amyloid of FAD cells treated or not with AFSC-EV for 7 days. These
data are obtained by measuring the Aβ42 levels via ELISA as described in Section 2.9. ∗∗∗p value < 0.001.
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production may have an integral role in the development of
sporadic AD prior to the appearance of amyloid and Tau
pathology [44].
The mechanisms proposed by de Godoy et al. [14] to
explain, at least in part, neuroprotection by MSC-EVs per-
tains to the content in antioxidant enzymes and in anti-
inflammatory and/or trophic molecules. The authors dem-
onstrated that EVs secreted by MSCs contain and carry
endogenous catalase that endows EVs of ROS scavenging
activity. Similarly, we clearly observed that SOD1 is con-
tained into AFSC-extracellular vesicles. SOD1 presence
might be one of the mechanisms of protection exerted
by extracellular vesicles in neurodegeneration, avoiding
an excess of reactive oxygen species. A decrease in reduced
glutathione (GSH) causes excess in ROS production lead-
ing to oxidative stress, thus favoring AD pathogenesis
[45]. Here, we demonstrated that exposure to AFSC-EV
induced a significant rise in glutathione peroxidase (Gpx)
enzyme; thus, it is not surprising to see that EV-
treatment increased GSH levels in FAD neurons. These
samples showed a slightly minor content of GSH, com-
pared to WT, in accordance with the data obtained by
Resende et al. in the 3xTg-AD mice, an AD mouse model,
where decreased levels of GSH were observed [46]. A sim-
ilar trend, even if not statistically significant, also occurred
in WT cells, when treated with EV. This slight difference
between WT and FAD neurons in GSH levels after 7 days
in culture is likely to be due to a cellular defense that can
be noticed in the expression increase of the antioxidant
enzyme thioredoxin reductase 1 (TrxR1). Moreover, both
TrxR1 and TrxR2 presence surged after EV-exposure, con-
tributing with SOD1 and Gpx to the ROS decrease
observed in these samples. This complex redox balance is
also influenced by the presence of prooxidant enzymes,
namely NADPH oxidases. In this experimental condition,
Nox4, the isoform constitutively active, showed a higher
content in FAD samples, being reduced, at least partially,
after EV-treatment. Regarding gp91phox, the specific sub-
unit of Nox2, no differences could be observed, perhaps
because the activation of this isoform derives mostly from
a regulating subunit interaction [27].
The analysis of our data demonstrated that extracellular
vesicles derived from stem cells have a direct effect on neu-
rons affected by AD, modulating ROS content. Meanwhile,
most of the literature shows an indirect therapeutic potential,
underlining a regulation of neuroinflammation reducing
microglial activation [47] [48] [49].
We have previously demonstrated that AFSC-
extracellular vesicles contain anti-inflammatory molecules,
namely, HFG, TGFβ, and pentraxin 3 [15] that showed a
therapeutic effect on osteoarthritis [16]. Even in this context,
pentraxin 3, that is, a protein regulator of angiogenesis and
neurogenesis with direct involvement in neuroinflammation
in acute phases [50], could have a therapeutic role. The pos-
itive effect of MSC secretome on both fronts, namely, neu-
rons and microglial cells, could be the winning key that
justifies the encouraging results obtained on AD features by
using MSCs in vivo. For example, the transplantation of
human umbilical cord blood and adipose-derived MSC, into
the hippocampus of mouse AD models, reduced Aβ plaques,
increased endogenous adult neurogenesis and synaptic activ-
ity, and enhanced cognitive function [51] [52].
5. Conclusions
In conclusion, in this study, we focused our attention on
extracellular vesicles in preventing the disease phenotypes
of the only neurons in culture. We employed cells deriving
from 5xFAD mice [53], a more complete animal model of
AD, if compared to Tg2576 from which primary neurons
were obtained in the study by Lee et al. [54]. Indeed,
Tg2576 is a mouse model carrying a single human amyloid
precursor protein mutation (APPswe) [55]. However, in
our model, the exposure of MSC extracellular vesicles ame-
liorated the progression of Aβ-induced neuronal death and
AD as well, supporting the idea proposed by Lee et al. that
extracellular vesicles, derived in that case from adipose tissue,
could exert disease-modulating effects [54]. Furthermore,
here, we clearly demonstrated a ROS regulation involvement
in extracellular vesicle therapeutic effect in neurodegenera-
tive diseases, such as AD.
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